On April 7, 2026 Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) (the "Company", "Sona") reported publication of a preclinical study using its Targeted Hyperthermia Therapy ("THT") to treat cancer, in the Journal of Nanobiotechnology which demonstrated treatment durability to the end of the 45 day study period when it was given in combination with immunotherapy. Building on its prior body of preclinical research treating melanoma and breast cancer (as published in Frontiers in Immunology), this study was conducted in an immunologically ‘cold’ colorectal cancer (CT26) tumor model. In this combination protocol, CT26 tumor-bearing animals were treated with two consecutive treatments of THT plus standard PD-1 inhibitor immunotherapy followed by three additional PD-1 treatments (the "Study"). Animals were followed for 45 days following initiation of treatment as per study protocol. At completion of the Study 38% of animals given the combined therapy were alive and disease free.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sona Nanotech CEO, David Regan commented, "We’ve all recently heard the shocking news that colon cancer is now the leading cause of cancer death for adults under 50. This timely preclinical evidence of strong immune activation in colon cancer using our THT/immunotherapy combination protocol reaffirms our confidence in pursuing Sona’s THT to spark immunity in typically immunotherapy resistant cancers. We are certainly proud of the quality of this peer-reviewed research and its acceptance in the highly respected Journal of Nanobiotechnology. This study, together with the safety and tolerability data from our recently completed, first-in-human study of THT as a monotherapy in melanoma, lays the foundation for our next trial that will combine our THT with immunotherapy."

Study principal investigator, lead author and Sona Chief Medical Officer, Dr. Carman Giacomantonio, commented, "We have focused our preclinical research on immunogenically cold cancers i.e. cancers that do not respond to today’s standard-of-care immunotherapy, to prove our hypothesis that Sona’s THT activates immunity. This is the third preclinical cancer-type in which we have confirmed our hypothesis, and our first publication delving deeply into the biology of our treatments. In this study, where no animals responded to a standard immunotherapy alone, 100% of animals in the THT treatment group responded to that same immunotherapy. This relates incredibly favorably to the less than ~15% success rate of immunotherapy when used to treat colorectal cancer in most humans due to low immunogenicity, giving us tremendous hope for its ability to change lives if translated successfully into a human therapy. Importantly, 38% (8 of 21) of those tumors completely cleared by day 24 following initiation of treatment and remained cancer-free to the end of the study. This is remarkably fast by any standard of measure, and these important findings will inform the protocol for our next clinical study."

(Press release, Sona Nanotech, APR 7, 2026, View Source [SID1234664211])